ABILIFY MYCITE® (aripiprazole tablets with sensor)

**LENGTH OF AUTHORIZATION:** THREE MONTHS

Abilify MyCite is a drug-device combination product comprised of aripiprazole and a sensor embedded in the tablets, intended to track drug ingestion. Most ingestions of Abilify MyCite will be detected within 30 minutes, but may take up to two hours to detect on the smartphone app. Its use is not for real time ingestion or emergency monitoring. Abilify MyCite has not been shown to improve patient adherence.

**REVIEW CRITERIA:**

- Patient is 18 years of age or older.
- Diagnosis of schizophrenia, bipolar I disorder, or major depressive disorder is documented.
- Must have documented non-compliance or non-response with at least two oral second generation antipsychotics, one of which is aripiprazole.
- Documentation of non-compliance not related to intolerance or allergic reaction to aripiprazole.

**DOSING:**

Schizophrenia: Initial dose of 10-15mg once daily with a maximum dose of 30mg once daily.
Bipolar: Initial dose of 10-15mg once daily with a maximum dose of 30mg once daily.
Major depressive disorder: Initial dose of 2-5mg once daily with a maximum dose of 15 mg once daily.

Tablets with sensor: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg

ABILIFY MYCITE is a first-of-its-kind treatment, so there will be limited product availability at launch. Otsuka America Pharmaceutical, Inc. is rolling out the ABILIFY MYCITE System in close collaboration with only a limited number of health plans and their affiliated doctors through this launch period. The doctors will be able to prescribe to those patients who are appropriate for the ABILIFY MYCITE System.¹

¹ [https://www.abilifymycite.com/initial-rollout](https://www.abilifymycite.com/initial-rollout)